Sporadic inclusion body myositis: New insights and potential therapy

Current Opinion in Neurology

Volumn 27, Issue 5, 2014, Pages 591-598

  Machado, Pedro M ^a   Dimachkie, Mazen M ^b   Barohn, Richard J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Inclusion body myositis; Myopathies; Pathogenesis; Treatment

Indexed keywords

ARIMOCLOMOL; AUTOANTIBODY; BIMAGRUMAB; FOLLISTATIN; MYOSTATIN; PROTEIN AGGREGATE; 5' NUCLEOTIDASE; ANTIBODY;

AUTOIMMUNITY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GENE THERAPY; HEAT SHOCK RESPONSE; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOSITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPORADIC INCLUSION BODY MYOSITIS; UPREGULATION; BLOOD; IMMUNOLOGY; MYOSITIS, INCLUSION BODY;

5'-NUCLEOTIDASE; ANTIBODIES; HUMANS; MAGNETIC RESONANCE IMAGING; MYOSITIS, INCLUSION BODY;

EID: 84925804758     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000129     Document Type: Review

References (54)

1. Gang Q, Bettencourt C, Machado P, et al. Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis 2014;9:88. Review of known and candidate genetic susceptibility risk factors for IBM.
2. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008;79:1056-1060.
3. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134(Pt 11):3176-3184.
4. Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Curr Opin Rheumatol 2013;25:763-771.
5. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep 2013;13:321.
6. Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013;15:329.
7. Lloyd TE. Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol 2010;22:658-664.
8. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008;18:6-16.
9. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010;12:221-228.
10. Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-447.
11. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009;19:493-506.
12. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011;6:e20266.
13. Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleo-tidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-418. Identification and diagnostic performance of autoantibodies against cN1A in IBM.
14. Pluk H, Van Hoeve BJ, Van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407. Identification and diagnostic performance of autoantibodies against cN1A in IBM.
15. Allenbach Y, Chaara W, Rosenzwajg M, et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS One 2014;9:e88788. Study describing the cytokine profile and the immune cell phenotype in IBM.
16. Georgantas RW, Streicher K, Greenberg SA, et al. Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis rheumatol 2014;66:1022-1033. Study investigating the role of miRNAs in the interplay between inflammation and degeneration in inflammatory myopathies.
17. Rygiel KA, Miller J, Grady JP, et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2014. [Epub ahead of print] Study investigating the prevalence of respiratory deficiency and its relationship to inflammation and atrophy in IBM.
18. Bua EA, McKiernan SH, Wanagat J, et al. Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol 2002;92:2617-2624.
19. Krishnan KJ, Reeve AK, Samuels DC, et al. What causes mitochondrial DNA deletions in human cells? Nat Genet 2008;40:275-279.
20. Cacciottolo M, Nogalska A, D'Agostino C, et al. Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres. Neuropathol Appl Neurobiol 2013;39:750-761.
21. Girolamo F, Lia A, Amati A, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2013;39:736-749.
22. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009;278:25-29.
23. D'Agostino C, Nogalska A, Cacciottolo M, et al. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusionbody myositis. Acta Neuropathol 2011;122:627-636.
24. D'Agostino C, Nogalska A, Engel WK, Askanas V. In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol 2011;37:315-320.
25. Ju JS, Weihl CC. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy 2010;6:283-285.
26. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010;23:482-488.
27. Ferrer I, Martin B, Castano JG, et al. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004;63:484-498.
28. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009;40:19-31.
29. Pinkus JL, Amato AA, Taylor JP, Greenberg SA. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul Disord 2014;24:611-616. Data suggesting abnormal RNA metabolism in IBM.
30. Cortese A, Plagnol V, Brady S, et al. Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy. Neurobiol Aging 2014;35:1491-1498. Data suggesting that widespread alterations of RNA metabolism have a pathogenic role in IBM.
31. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006;34:406-416.
32. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008;18:27-33.
33. Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a singlestranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994;144:874-882.
34. Olive M, Janue A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009;68:262-273.
35. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;339:b2680.
36. Griggs RC, Askanas V, Di Mauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713.
37. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013;84:1240-1246. Study describing and comparing the clinical assessment and histopathological findings at presentation and investigating disease progression in IBM patients.
38. Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: inclusion Body myositis, 2-4 2011 December Naarden, the Netherlands. Neuromuscul Disord 2013;23:1044-1055. Report of an international workshop that resulted in the publication of revised research diagnostic criteria for IBM.
39. Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014;4:e004552. Study evaluating the diagnostic utility of a number of markers of protein aggregates together with mitochondrial and inflammatory changes in IBM.
40. Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 2013;1:29. Quantitative study of the diagnostic value of LC3, p62 and TDP-43 immunohistochemistry in IBM.
41. Greenberg SA. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014. [Epub ahead of print]
42. Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010;20:2447-2460.
43. Cantwell C, Ryan M, O'Connell M, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI. Clin Radiol 2005;60:261-267.
44. Cox FM, Reijnierse M, Van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology 2011;50:1153-1161.
45. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve 2001;24:1526-1534.
46. Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1997;48:863-866.
47. Reimers CD, Schedel H, Fleckenstein JL, et al. Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 1994;241:306-314.
48. Smith RC, Lin BK. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care 2013;7:352-360.
49. Wojcik S, Engel WK, McFerrin J, Askanas V. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 2005;110:173-177.
50. Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with an anti-activin receptor IIB antibody. Ann Neurol 2013;74:S93-S94.
51. Efficacy and safety of bimagrumab/BYM338 at 52 weeks on physical function, muscle strength, mobility in sIBM patients (RESILIENT). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01925209. [Accessed 20 June 2014]
52. Hogrel JY, Allenbach Y, Canal A, et al. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials. Neuromuscul Disord 2014;24:604-610.
53. Follistatin gene transfer to patients with Becker muscular dystrophy and sporadic inclusion body myositis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01519349. [Accessed 20 June 2014]
54. Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial. Ann Rheum Dis 2013;72:A164.